Portfolio Overview
Total NAV
CHF 2.4B
+8.2%
Outperforming NBI by 3.1%
Net Asset Value as of Dec 2024
Trials Monitored
142
+12
5 Phase 3 readouts pending
Trial Watchdog active monitoring
AI Alerts Today
7
2 Critical
ARGX Phase 3 data released
Sentiment Scout + Trial Watchdog
Portfolio Beta
1.12
-0.05
Lower volatility exposure
vs NBI benchmark
NAV Performance vs Benchmark
Portfolio NAV compared to Nasdaq Biotechnology Index (NBI)
Sector Allocation
Portfolio exposure by therapeutic area
RNA Therapeutics29%
Oncology23%
Neurology15%
Autoimmune14%
Rare Disease13%
Metabolic6%
Top Holdings
Portfolio positions with AI sentiment analysis
| Company | Ticker | Allocation | Value (CHF) | Change | AI Sentiment | Focus | |
|---|---|---|---|---|---|---|---|
| Ionis Pharmaceuticals | IONS | 14.6% | 350.4M | +2.8% | Very Positive | RNA Therapeutics | |
| Argenx SE | ARGX | 14.1% | 338.4M | +1.4% | Very Positive | Autoimmune | |
| Revolution Medicines | RVMD | 9.3% | 223.2M | +5.2% | Very Positive | Oncology | |
| Neurocrine Biosciences | NBIX | 8.8% | 211.2M | -0.8% | Neutral | Neurology | |
| Alnylam Pharmaceuticals | ALNY | 7.1% | 170.4M | +3.6% | Very Positive | RNAi Therapeutics | |
| Vertex Pharmaceuticals | VRTX | 6.4% | 153.6M | +0.4% | Positive | Rare Disease | |
| Agios Pharmaceuticals | AGIO | 5.3% | 127.2M | +1.2% | Positive | Rare Disease | |
| Incyte Corporation | INCY | 4.4% | 105.6M | -0.2% | Neutral | Oncology | |
| Scholar Rock | SRRK | 4.3% | 103.2M | +2.1% | Positive | Neurology | |
| Akero Therapeutics | AKRO | 4% | 96.0M | +4.8% | Very Positive | Metabolic |